(Q39067664)

8 September 2017

title

Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression (English)

1 reference

8 September 2017

6

N Nemat Gorgani

1 reference

8 September 2017

E Drewniany

1

1 reference

8 September 2017

J Han

2

1 reference

8 September 2017

C Hancock

3

1 reference

8 September 2017

R L Jones

4

1 reference

8 September 2017

J Lim

5

1 reference

8 September 2017

J K Sperry

7

1 reference

8 September 2017

H J Yu

8

1 reference

8 September 2017

R B Raffa

9

1 reference

8 September 2017

publication date

26 December 2014

1 reference

Journal of Clinical Pharmacy and Therapeutics

8 September 2017

published in

1 reference

8 September 2017

volume

40

1 reference

8 September 2017

issue

2

1 reference

8 September 2017

page(s)

125-130

1 reference

Intravenous ketamine for treatment-resistant major depressive disorder.

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Ketamine as a novel antidepressant: from synapse to behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Ketamine as antidepressant? Current state and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

A 40-year perspective on the prevalence of depression: the Stirling County Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Gender differences in unipolar depression: an update of epidemiological findings and possible explanations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Natural history of Diagnostic Interview Schedule/DSM-IV major depression. The Baltimore Epidemiologic Catchment Area follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Mindfulness-based cognitive therapy: evaluating current evidence and informing future research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Review: Cognitive behavioural therapy for adolescents with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Cognitive therapy in relapse prevention in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Antidepressant drug effects and depression severity: a patient-level meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

A systematic review of comparative efficacy of treatments and controls for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Medication augmentation after the failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

21 January 2018

Ketamine use: a review

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

The messenger RNAs for the N-methyl-D-aspartate receptor subunits show region-specific expression of different subunit composition in the human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Magnetic Resonance Spectroscopy Studies of Glutamate-Related Abnormalities in Mood Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Antidepressant effects of ketamine in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

An open-label, flexible-dose study of memantine in major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

A double-blind, placebo-controlled study of memantine in the treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Role of brain-derived neurotrophic factor in the aetiology of depression: implications for pharmacological treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Mood regulation. GABA/glutamate co-release controls habenula output and is modified by antidepressant treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

In vivo ketamine-induced changes in [¹¹C]ABP688 binding to metabotropic glutamate receptor subtype 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Ketamine : from medicine to misuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Repeated S-ketamine infusions in therapy resistant depression: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

The catecholamine hypothesis of affective disorders: a review of supporting evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Use of bupropion in combination with serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

A neurotrophic model for stress-related mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Brain-derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Deficit in BDNF does not increase vulnerability to stress but dampens antidepressant-like effects in the unpredictable chronic mild stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Enhancement of translation elongation in neurons by brain-derived neurotrophic factor: implications for mammalian target of rapamycin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

A molecular mechanism for the effect of lithium on development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Augmentation strategies for treatment-resistant depression: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Upstream and downstream of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

mTOR signaling: at the crossroads of plasticity, memory and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

Linkage mapping of serotonin transporter protein gene SLC6A4 on chromosome 17

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12238

21 January 2018

Identifiers

DOI

10.1111/JCPT.12238

1 reference

8 September 2017

1 reference